All parainfluenza virus 5 articles
-
News
Intranasal COVID-19 vaccine headed to clinical trials
CyanVac will sponsor a randomized, double-blind Phase 2b study to compare the efficacy and safety of CVXGA, its intranasal vaccine candidate designed to protect against COVID-19, against an FDA-approved mRNA-based COVID-19 vaccine.